Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (OPTI-FLIP) - this hivrad program will develop an HIV vaccine regimen that is based on cooperative…

Active Grant Awarded Last action

Award ID
P01AI181044
Recipient
Awarding agency
Obligated
$7,547,265

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 39% complete
Place of performance
Davis, CA, USA

Award details come from USAspending.gov.

Description

Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (OPTI-FLIP) - this hivrad program will develop an HIV vaccine regimen that is based on cooperative interactions between ENV fusion peptide (FP)-directed antibodies and follicle-homing helper and cytotoxic T cells. We will use innovative vaccine modalities and adjuvants that are designed to elicit high-quality T cells in support of anti-FP antibodies. Strategies for eliciting broadly neutralizing antibodies (BNABS) against HIV have made substantial progress. There are indications that germline targeting, divided doses, mrna vaccination, and other strategies may all contribute to the goal of reliably eliciting BNABS in humans. If these strategies are successful, however, the elicited BNABS will likely be of lower titer than required to protect against HIV. An effective vaccine will therefore elicit a concomitant high-quality T-cell response, in addition to BNABS. The proposed research program combines investigation of cooperative antibody and T-cell responses in people with testing innovative tools for eliciting helper and cytotoxic T cells that are distinguished, not by magnitude, but rather by longevity, localization to B-cell follicles, functional effector functions and/or avidity. Project 1 will examine humoral responses and follicular T cells in human beings receiving combined sosip/HTI vaccines, and will examine the anti-FP responses that contribute to effective HIV neutralization in clade C-infected people. Project 2 will leverage IL-10 inhibitors to safely elicit high-quality CD8+ T cells-and will then selectively boost cells of higher avidity. Project 3 will use immunogens that are targeted to TF cells and/or mucosal surfaces to elicit anti-FP BNABS that are supported by high-intensity TF responses. As a culmination, P3 will also integrate information from all program components to test a new "cooperative" vaccine regimen in macaques. A shared objective of our program is to test the influence of pre-existing TF responses on humoral responses to vaccination, and examine if CD8+CXCR5+ T cells contribute meaningful helper function. A second major objective is to evaluate the importance of T-cell avidity for both follicular-helper and cytotoxic functions. A third collective goal is to understand how FP-directed antibodies contribute to protective breadth against clade-C HIV envelopes.

Transactions

Action Obligated Date
Amendment $194,227
Amendment $511,076
Amendment $3,289,342
Amendment $0
Original award $3,552,620

Subawards

Subrecipient Amount Awarded
The Trustees Of Columbia University In The City Of New York Scope of Work The Kwong-Shapiro team will carry out structural analyses on elicited neutralizing antibodies, in specific providing single particle cryo-EM… $481,798
Tendel Therapies Inc. HIV FP cocktail vaccines designed for optimal follicular T and B cell induction and efficacy (Opti-FliP) $585,352
Fundacio Privada Institut De Recerca Sobre Immunopatologies-Caixa Irsicaixa Statement of work The work at Irsicaixa will seek to identify individuals with accelerated neutralization activity to HIV, and to define the ENV sequences of… $511,076
Emory University Statement of work 1) Encapsulate mRNAs that we provide into 10 different mRNA/LNP vaccine batches of $216,802
The Trustees Of Columbia University In The City Of New York The Kwong-Shapiro team will carry out structural analyses on elicited neutralizing antibodies, in specific providing single particle cryo-EM analyses for the… $111,696
University Of New Mexico The Chackerian Laboratory at the University of New Mexico School of Medicine will be responsible for producing Virus-like Particle based vaccines displaying the… $289,575
Wits Health Consortium (Pty) LTD Core 1 Scope of Work A major challenge in the HIV vaccine field is to determine how to elicit antibodies that can block HIV infection. Studies of HIV infection,… $351,474
Fundacio Privada Institut De Recerca Sobre Immunopatologies-Caixa Irsicaixa Statement of work The work at Irsicaixa will seek to identify individuals with accelerated neutralization activity to HIV, and to define the ENV sequences of… $385,744

Quick answers

Who received award P01AI181044?

P01AI181044 was awarded to University Of California, Davis by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 17, 2024.

How much is award P01AI181044 worth?

$7,547,265 has been obligated on P01AI181044.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award